2013 Fiscal Year Final Research Report
Experimental research on the development of new treatment strategies for triple negative breast cancer
| Project/Area Number |
23591911
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Kawasaki Medical School |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
MORIYA Takuya 川崎医科大学, 医学部, 教授 (00230160)
KANOMATA Naoki 川崎医科大学, 医学部, 准教授 (60263373)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Keywords | 乳癌 / トリプルネガティブ・サブタイプ / PARP阻害薬 / mTOR阻害薬 / 癌幹細胞 |
|---|
| Research Abstract |
We conducted experimental studies to investigate anti-tumor activity of a poly-ADP-ribose polymerase (PARP) 1 inhibitor olaparib and a mTOR inhibitor everolimus (EVE) using breast cancer cell lines. We also investigated the effects of the agents on the ratio of CSC. Olaparib possesses growth inhibitory activity in not only TNBC cell lines but also ER-positive, HER2-negative cell lines. A combined treatment of olaparib with antiestrogen (AE) rendered an additive growth inhibitory effect in ER-positive cell lines. Anti-tumor activity of EVE was investigated using a panel of human breast cancer cell lines of various subtypes. EVE possessed a drastic growth inhibitory effect on a BRCA1-mutated, TNBC cell line and also exhibited a moderate growth inhibitory effect on a part of ER-positive breast cancer cells lines. EVE tended to decrease the ratio of CSC in most cell lines.
|
Research Products
(26 results)
